A multi-center, open-label clinical pharmacology study for comparative investigation of the pharmacokinetics, tolerability, and safety of three types of brexpiprazole (OPC-34712) once-weekly (QW) formulation administered as single oral doses in patients with schizophrenia
Latest Information Update: 25 Apr 2025
At a glance
- Drugs Brexpiprazole (Primary)
- Indications Schizophrenia
- Focus Pharmacokinetics
- Sponsors Otsuka Pharmaceutical
Most Recent Events
- 17 Apr 2025 Status changed from active, no longer recruiting to completed.
- 10 Feb 2025 Status changed from recruiting to active, no longer recruiting.
- 04 Nov 2024 Planned End Date changed from 1 Jan 2025 to 1 May 2025.